Testicular Neoplasms Clinical Trial
Official title:
Effect of Online Education Given to Young Adults on Testicular Cancer Health Beliefs and Behaviors
Verified date | October 2022 |
Source | Agri Ibrahim Cecen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Aim: One of the cheapest, easiest and most effective ways to detect testicular cancer early is to resort to early detection screening methods associated with health beliefs about testicular cancer, and the second is to self-examine the testicles. In the country, there are a limited number of studies on the health beliefs and early diagnosis behaviors of young adult men for testicular cancer. For this reason, the study was conducted to determine the effect of online education given to young adults on testicular cancer health beliefs and behavior. Material and method: The research was conducted as a randomized controlled experimental study. The study population consisted of 768 individuals who applied to Family Health Centers affiliated to Agri Provincial Health Directorate between April 2021 and June 2022, and the sample of the research consisted of 90 individuals selected from the population using the improbable random sampling method. "Descriptive Feature Form", "Champion's Health Belief Model Scale in Testicular Cancer Screenings" were used to collect data. In the analysis of data; percentile distribution, chi-square, Fisher-Freeman-Halton Exact test, t-test in independent groups, Repeated Measures ANOVA Test, Friedman Test, One Way ANOVA test, Kruskall Wallis test, and post hoc analyzes (Bonferroni, Games Howell, Dunn) were used.
Status | Completed |
Enrollment | 90 |
Est. completion date | September 28, 2022 |
Est. primary completion date | September 28, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Being 18-35 years old, - Being literate, - Computer can be used, - Being able to access the Internet, - Not having a testicular diagnosis before, - Deciding to participate in the research. Exclusion Criteria: - Being outside the age range of 18-35, - To be diagnosed with testicular cancer before |
Country | Name | City | State |
---|---|---|---|
Turkey | Agri Ibrahim Cecen University | Agri |
Lead Sponsor | Collaborator |
---|---|
Agri Ibrahim Cecen University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Giving training to the experimental group for 6 weeks with an interval of 2 weeks. | Individuals in the experimental and control group were evaluated with "Champion's Health Belief Model Scale in Testicular Cancer Screening". The effect of the training given to people in the online training group, which cannot be given to the control group, was changed at the end of 16 weeks with the mid-test "Champion's Health Belief Model Scale in Testicular Cancer Screening". A minimum of 26 points and a maximum of 130 points are obtained from Champion's Health Belief Model Scale in Testicular Cancer Screenings. The sub-dimensions of the scale are evaluated separately and there is no total score. | Four monts | |
Primary | Collection of the final test | The mid-test for individuals in the experimental and control group was evaluated by the "Champion's Health Belief Model Scale in Testicular Cancer Screening". The effect of training given to those who could not be given to the control group in the online training group was replaced by the "Champion's Health Belief Model Scale in Testicular Cancer Screening" final test 3 months after training. A minimum of 26 points and a maximum of 130 points are obtained from Champion's Health Belief Model Scale in Testicular Cancer Screenings. The sub-dimensions of the scale are evaluated separately and there is no total score. | Three monts |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00231582 -
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
|
Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Terminated |
NCT02577172 -
Testicular Cancer and Aerobic and Strength Training
|
N/A | |
Completed |
NCT03403777 -
Avelumab in Refractory Testicular Germ Cell Cancer.
|
Phase 2 | |
Completed |
NCT02890030 -
The Platinum Study Comparison Group
|
||
Recruiting |
NCT05264337 -
Lymphedema After Urologic Surgery
|
||
Active, not recruiting |
NCT03426865 -
Role of Axumin PET Scan in Germ Cell Tumor
|
||
Completed |
NCT00001270 -
Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
|
Phase 1 | |
Completed |
NCT02459132 -
High-Intensity Aerobic Interval Training in Testicular Cancer Survivors
|
N/A | |
Completed |
NCT06309732 -
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
|
Phase 2 | |
Terminated |
NCT02499952 -
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
|
Phase 2 | |
Recruiting |
NCT02304575 -
Quality of Life Among Testicular Cancer Survivors
|
N/A | |
Withdrawn |
NCT02492360 -
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
|
N/A | |
Completed |
NCT04122430 -
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours
|
||
Recruiting |
NCT02229916 -
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
|
||
Completed |
NCT02161692 -
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
|
Phase 2 | |
Completed |
NCT02966509 -
Engagement of Patients With Advanced Cancer
|
N/A | |
Recruiting |
NCT02341989 -
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
|
Phase 3 | |
Terminated |
NCT05229900 -
A Study of SGN-ALPV in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00123773 -
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
|
Phase 2 |